Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

Background Immune-mediated diarrhea and colitis (IMDC) is currently diagnosed and monitored by evaluating clinical symptoms. Deep remission is determined by endoscopic and histologic evaluation of the disease process. However, repeating these invasive procedures frequently can become cumbersome. We...

Full description

Bibliographic Details
Main Authors:	Jennifer Wang, John A Thompson, Yinghong Wang, Hao Chi Zhang, Fangwen Zou, Jennifer L McQuade, Anusha S Thomas, Isabella C Glitza Oliva
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/1/e002058.full

Similar Items

Correction: Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
by: Dimitrios C Ziogas
Published: (2021-03-01)

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
by: Xuemei Wang, et al.
Published: (2021-11-01)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
by: Renske W. M. Pauwels, et al.
Published: (2020-12-01)

Beyond histological remission: the role of mucosal calprotectin as a potential predictor of outcomes in ulcerative colitis.
by: Guirgis, M, et al.
Published: (2016)

Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis
by: Xiaoqi Ye, et al.
Published: (2021-02-01)

Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission
by: Mimari Kanazawa, et al.
Published: (2021-10-01)

Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis
by: Dong Ju Kim, et al.
Published: (2018-10-01)

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis
by: Sun-Ho Lee, et al.
Published: (2017-10-01)

Utility of fecal calprotectin as a discriminative biomarker between ulcerative colitis and irritable bowel syndrome and its ability to be used for the assessment of the remission stage of ulcerative colitis
by: Hossam M Elsaadany, et al.
Published: (2016-01-01)

Possible Correlation between Giardia duodenalis Genotypes and Fecal Calprotectin in Children with Diarrhea
by: Hanan M Abou-Seri, et al.
Published: (2022-12-01)

Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
by: Mahsa Mahdipour, et al.
Published: (2019-04-01)

Is histological remission of ulcerative colitis achievable?
by: Oleg V. Knyazev, et al.
Published: (2021-08-01)

HOW MUCH AGREEMENT IS THERE BETWEEN HISTOLOGICAL, ENDOSCOPIC AND CLINICAL ASSESSMENTS OF REMISSION IN ULCERATIVE COLITIS?
by: Thomas, S, et al.
Published: (2009)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
by: Aaron G. Issac, et al.
Published: (2022-06-01)

Correlation between gut pathogens and fecal calprotectin levels in young children with acute diarrhea
by: Yanever Angela Lam, et al.
Published: (2014-08-01)

Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
by: Nagesh Kamat, et al.
Published: (2022-04-01)

Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis - a prospective analysis
by: Walsh, A, et al.
Published: (2018)

Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome.
by: Takahiko Toyonaga, et al.
Published: (2017-01-01)

Fecal <i>Filobasidium</i> Is Associated with Clinical Remission and Endoscopic Response following Fecal Microbiota Transplantation in Mild-to-Moderate Ulcerative Colitis
by: Isabelle A. M. van Thiel, et al.
Published: (2022-03-01)

Associations between Pouchitis and Fecal Calprotectin after Restorative Proctocolectomy in Patients with Ulcerative Colitis
by: Motoi Uchino, et al.
Published: (2023-07-01)

Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome
by: von Arnim U, et al.
Published: (2016-04-01)

Fecal calprotectin and microbiota of the gut
by: V. G. Gorokhova, et al.
Published: (2016-07-01)

Fecal Calprotectin Is Increased in Stroke
by: Shin Young Park, et al.
Published: (2021-12-01)

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2018-09-01)

Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome
by: Hamid Kalantari, et al.
Published: (2015-01-01)

Experimental infectious challenge in pigs leads to elevated fecal calprotectin levels following colitis, but not enteritis
by: Jéssica A. Barbosa, et al.
Published: (2021-08-01)

Role of fecal calprotectin as a biomarker of intestinal inflammation in ulcerative colitis: a prospective study
by: Onişor Danusia, et al.
Published: (2018-07-01)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
by: Timo Rath, et al.
Published: (2023-10-01)

Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test: A Systematic Review and Meta-analysis
by: Tingpeng Hu, et al.
Published: (2023-09-01)

Fecal calprotectin in inflammatory bowel disease
by: Walsham NE, et al.
Published: (2016-01-01)

Fecal Calprotectin in Inflammatory Bowel Disease
by: Jun Lee
Published: (2016-05-01)

EVALUATION OF HISTOLOGICAL PARAMETERS IN PATIENTS WITH CLINICAL REMISSION OF ULCERATIVE COLITIS
by: O. B. Shchukina, et al.
Published: (2014-11-01)

Real-life evaluation of histologic scores for Ulcerative Colitis in remission.
by: Christian Børde Arkteg, et al.
Published: (2021-01-01)

The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine
by: Giuseppe Frieri, et al.
Published: (2017-10-01)

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease
by: Francisco Guilherme Cancela e Penna, et al.
Published: (2020-02-01)

Fecal calprotectin as an indicator in risk stratification of pouchitis following ileal pouch–anal anastomosis for ulcerative colitis
by: Rui-Bin Li, et al.
Published: (2023-12-01)

Correlation between the Ulcerative Colitis Endoscopic Index of severity (UCEIS) and intestinal mucosal calprotectin (IMC) in acute severe ulcerative colitis.
by: Chamoun, J, et al.
Published: (2015)

Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin
by: Juan María Vázquez-Morón, et al.

Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis
by: Yuen Sau Tham, et al.
Published: (2018-06-01)

Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission
by: Corina Silvia Pop, et al.
Published: (2020-12-01)